Beyond Air's Cancer Bet: Nitric Oxide Therapy Enters Key Trial Phase

GARDEN CITY, NY – February 04, 2026 – Biotechnology firm Beyond Cancer, Ltd. is preparing to step into the spotlight at a major scientific conference, announcing it will present the first look at human trial data for its novel cancer therapy. The company, a subsidiary of the publicly traded Beyond Air, Inc. (NASDAQ: XAIR), confirmed that Phase 1 data for its intratumoral Ultra-High Concentration Nitric Oxide (UNO) treatment will be unveiled at the American Association for Cancer Research (AACR) Annual Meeting in April 2026.

This presentation marks a critical juncture for a company aiming to repurpose a well-known biological molecule into a new weapon against solid tumor metastases, one of the most challenging areas in oncology. The abstract, scheduled for a sneak peek release on March 17, will be presented by Dr. Amichay Meirovitz of Soroka University Medical Center, offering the first clinical validation of a therapy that has, until now, been developed in preclinical studies.

The Science of High-Dose Nitric Oxide

Nitric oxide (NO) is a molecule with a famously paradoxical reputation in cancer biology. At low, chronic levels, it has been linked to tumor growth and progression. However, at the ultra-high concentrations being harnessed by Beyond Cancer, its properties are reported to be powerfully anticancer. The company's UNO therapy is designed to deliver this potent dose directly into a tumor, leveraging a proprietary delivery system to overcome the historical challenge of controlling NO concentration.

The scientific premise is threefold. First, at these high doses, NO acts as a direct cytotoxic agent, capable of inducing tumor cell death through processes like apoptosis. Second, it functions as an immunomodulator, aiming to transform the tumor's local environment from a haven for cancer cells into a hostile territory that attracts and activates the body’s own immune system. This could potentially inhibit key immune-evasion pathways, making the cancer vulnerable to attack. Finally, UNO is being investigated for its potential to act as both a chemosensitizer and a radiotherapy enhancer, meaning it could make existing standard-of-care treatments more effective, particularly against resistant tumors.

This multi-pronged mechanism is what distinguishes the approach. By injecting UNO directly into a tumor, the goal is to achieve a potent local effect while minimizing the systemic toxicities that often plague conventional cancer treatments like chemotherapy.

Deciphering the Phase 1 Data

The upcoming AACR presentation will feature data from a first-in-human, Phase 1 trial. In the world of drug development, Phase 1 studies are primarily designed to answer one fundamental question: is the treatment safe? Researchers will be looking closely at the therapy's safety profile, tolerability, and any dose-limiting side effects. For an intratumoral injection, this also involves ensuring the high concentration of nitric oxide remains localized, with minimal leakage into the systemic circulation.

While safety is the primary endpoint, all eyes will be on any secondary signals of efficacy. For a therapy targeting metastatic solid tumors—a patient population with significant unmet needs—even modest signs of anticancer activity are considered highly promising at this early stage. Observers will be looking for data on tumor shrinkage at the injection site, but the ultimate prize would be evidence of an “abscopal effect.” This phenomenon, highly sought after in immunotherapy, occurs when treating a single tumor sparks a systemic immune response that attacks and shrinks other metastatic lesions throughout the body.

Any indication of stable disease, partial responses, or changes in biomarkers that confirm the drug is engaging its target as intended would be viewed as a significant validation of the UNO platform and a green light for further development.

A Strategic Pivot into Oncology

The UNO program represents a significant strategic expansion for parent company Beyond Air. Primarily known for its expertise in respiratory medicine, Beyond Air has already achieved commercial success with its FDA-approved LungFit PH system, which uses nitric oxide to treat respiratory failure in newborns. The foray into oncology via its subsidiary Beyond Cancer is a calculated bet to leverage its core competency in NO technology in a vast and lucrative market.

This diversification is not without risk and requires substantial investment. Beyond Air's financial filings show a company in a high-growth phase, with fiscal year 2025 revenue jumping 220% to $3.7 million. However, it also reported a net loss of over $46 million in the same period, reflecting the heavy research and development costs typical of the biotech industry. The success or failure of the UNO program will have a substantial impact on the company's valuation and long-term trajectory.

Analysts see this move as a high-stakes, high-reward venture. A positive readout from the Phase 1 trial could attract significant investor interest and potential partnership opportunities, validating the company's strategy to build a broad therapeutic platform on the foundation of nitric oxide.

Navigating a Competitive Field

Beyond Cancer enters a dynamic and increasingly crowded field of intratumoral therapies. The concept of directly attacking tumors to stimulate a systemic immune response has gained significant traction, with a market projected to grow exponentially in the coming decade. The competitive landscape includes a variety of approaches, from oncolytic viruses that infect and destroy cancer cells, such as Amgen's approved therapy IMLYGIC, to cytokine-based treatments like OncoSec Medical's TAVO, which uses Interleukin-12 to rally an immune response.

Other competitors are developing novel formulations of chemotherapy for direct injection or using agonists that trigger specific innate immune pathways. In this context, Beyond Cancer’s UNO therapy must demonstrate a clear advantage, whether in safety, efficacy, ease of use, or its ability to combine effectively with other treatments. Its unique mechanism, rooted in the complex biology of nitric oxide, provides a point of differentiation.

The full details to be presented on April 19th will provide the first concrete evidence of how UNO performs in human subjects. This data will be crucial for determining its path forward and its potential place within the evolving arsenal of cancer treatments. For patients, investors, and the oncology community, the upcoming abstract release on March 17th will be the first chapter in what could be a compelling new story in the fight against metastatic cancer.